
Invitae Corporation NVTA
Quarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Total Inventories 2011-2026 | NVTA
Annual Total Inventories Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 30.4 M | 33.5 M | 32 M | 6.6 M | 8.3 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.5 M | 6.6 M | 22.2 M |
Quarterly Total Inventories Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.6 M | 20.8 M | 19.1 M | 30.4 M | 29.9 M | 49.1 M | 43.5 M | 33.5 M | 30.6 M | 30 M | 30.7 M | 32 M | 32 M | 32 M | 32 M | 6.65 M | 6.6 M | 6.6 M | 6.6 M | 8.3 M | 8.3 M | 8.3 M | 8.3 M | 5.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.1 M | 5.4 M | 22.2 M |
Total Inventories of other stocks in the Diagnostics research industry
| Issuer | Total Inventories | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Bioventus
BVS
|
82.2 M | $ 8.98 | 1.18 % | $ 598 M | ||
|
Castle Biosciences
CSTL
|
8.14 M | $ 26.0 | 0.64 % | $ 722 M | ||
|
Aspira Women's Health
AWH
|
316 K | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
629 M | $ 68.09 | 2.64 % | $ 26.6 B | ||
|
Guardant Health
GH
|
85.9 M | $ 88.7 | 1.74 % | $ 11.1 B | ||
|
Charles River Laboratories International
CRL
|
299 M | $ 155.4 | 2.26 % | $ 7.7 B | ||
|
CareDx, Inc
CDNA
|
26.7 M | $ 17.57 | 1.44 % | $ 936 M | ||
|
ICON Public Limited Company
ICLR
|
2.3 M | $ 101.48 | 3.96 % | $ 8.37 B | ||
|
Accelerate Diagnostics
AXDX
|
5.19 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
166 M | $ 103.94 | 0.08 % | $ 19.6 B | ||
|
Global Cord Blood Corporation
CO
|
45.9 M | - | - | $ 399 M | ||
|
Neogen Corporation
NEOG
|
191 M | $ 9.37 | 2.85 % | $ 2.03 B | ||
|
Danaher Corporation
DHR
|
2.49 B | $ 194.76 | 1.76 % | $ 139 B | ||
|
Biocept
BIOC
|
757 K | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
60 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
909 K | - | -20.0 % | $ 1.06 M | ||
|
Pacific Biosciences of California
PACB
|
49.3 M | $ 1.4 | 3.16 % | $ 420 M | ||
|
Illumina
ILMN
|
547 M | $ 121.73 | 2.05 % | $ 19.4 B | ||
|
Quest Diagnostics Incorporated
DGX
|
189 M | $ 199.39 | 0.23 % | $ 22.1 B | ||
|
QIAGEN N.V.
QGEN
|
279 M | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
830 M | $ 113.69 | 1.66 % | $ 34.6 B | ||
|
BioNano Genomics
BNGO
|
13.3 M | $ 1.12 | 0.9 % | $ 1.42 M | ||
|
DarioHealth Corp.
DRIO
|
5.06 M | $ 9.28 | 10.24 % | $ 263 M | ||
|
Lantheus Holdings
LNTH
|
64.7 M | $ 78.71 | 0.26 % | $ 5.31 B | ||
|
Chembio Diagnostics
CEMI
|
7.72 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
1.66 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Motus GI Holdings
MOTS
|
496 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
387 M | $ 1 218.18 | 1.62 % | $ 25.1 B | ||
|
DermTech
DMTK
|
1 M | - | -11.32 % | $ 2.94 M | ||
|
Twist Bioscience Corporation
TWST
|
28.3 M | $ 46.28 | 2.82 % | $ 2.77 B | ||
|
NeoGenomics
NEO
|
28.6 M | $ 8.41 | 2.06 % | $ 1.08 B | ||
|
Enzo Biochem
ENZ
|
6.83 M | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
35.4 M | $ 201.38 | 1.87 % | $ 19.8 B |